Scorpion Therapeutics, Inc.

Clinical-stage precision oncology company developing targeted therapies for cancer patients using advanced tech in biology, chemistry, and data science. Pipeline includes clinical candidates for undruggable targets; Lilly acquired PI3Kα inhibitor STX-478 program in 2025.